Format

Send to

Choose Destination
Lancet. 2017 Jan 14;389(10065):197-210. doi: 10.1016/S0140-6736(16)30677-8. Epub 2016 Aug 5.

Acute myocardial infarction.

Author information

1
Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
2
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Executive Director Cardiometabolic Trials, Harvard Clinical Research Institute, Boston, MA, USA. Electronic address: christopher.cannon@hcri.harvard.edu.

Erratum in

Abstract

Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the overall management of acute myocardial infarction can be reviewed for simplicity. Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide, despite substantial improvements in prognosis over the past decade. The progress is a result of several major trends, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as statins. This seminar discusses the important topics of the pathophysiology, epidemiological trends, and modern management of acute myocardial infarction, focusing on the recent advances in reperfusion strategies and pharmacological treatment approaches.

Comment in

PMID:
27502078
DOI:
10.1016/S0140-6736(16)30677-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center